Navigation Links
UIC chemists characterize Alzheimer's neurotoxin structure
Date:12/3/2007

Amyloid plaques, the hallmark of Alzheimer's disease, are clumps of fiber-like misfolded proteins which many experts think cause this devastating neurodegenerative disease.

While effective treatment remains an elusive goal, new research by University of Illinois at Chicago chemists suggests a possible new approach.

Yoshitaka Ishii, associate professor of chemistry, and his students managed to capture and characterize a crucial intermediate step in the formation of amyloid plaque fibers, or fibrils, showing tiny spheres averaging 20 nanometers in diameter assembling into sheet-like structures comparable to that seen in formation of fibrils.

Fibrils made of small proteins called amyloid-beta are toxic to nerve cells, but intermediate spheres, including those identified by Ishii's group, are more than 10 times as poisonous. That has made the spherical intermediates a new suspect for causing Alzheimer's disease.

"The problem with studying the structure of this intermediate form is that it's so unstable," said Ishii. His team's approach, he said, was to 'freeze-trap' the fleeting intermediate form, then use solid-state nuclear magnetic resonance to determine its structure and electron microscopes to study its morphology, or shape.

Ishii and his coworkers confirmed that the intermediate spherical stage of amyloid is more toxic than the final-form fibrils. Their findings are the first to pinpoint sheet formation at the toxic intermediate stage in the misfolding of the Alzheimer's amyloid protein and support the notion that the process of forming the layered sheet structure might be what triggers toxicity and kills nerve cells.

"Our method characterized the detailed molecular structure of this unstable, intermediate species," Ishii said. "To the best of our knowledge, this is the first characterization of detailed molecular structures for toxic amyloid intermediates. We found that the structure was very similar to the final (fibril) form, which wasn't expected at all."

Ishii said a complete determination of the intermediate structure remains to be done, but he is confident his lab will be able to do that. Once completed, the findings may provide pharmaceutical manufacturers with the information they need to create drugs that will prevent interaction between the toxic molecules and nerve cells.

Ishii said the method can also be applied to structural studies of proteins associate with other neurodegenerative diseases, including Parkinson's, and prion diseases, such as Creutzfeldt-Jakob.

"We're also interested in applying our technique in the nanoscience field to examine the formation process of peptide-based nano-assemblies," he said.


'/>"/>

Contact: Paul Francuch
francuch@uic.edu
312-996-3457
University of Illinois at Chicago
Source:Eurekalert

Related medicine news :

1. Computers help chemists fight emerging infections
2. HIDA Calls for Scrutiny of Group Purchasing Organization Distributor Fee Structure
3. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
4. Purdue Pharma Selects Systech to Provide Sustainable Infrastructure for Serialization
5. Smart insulin nanostructures pass feasibility test, UT study reports
6. CRC Health Group Announces Acquisition of Durhams Structure House, Weight Loss Facility
7. Fallon Community Health Plan Selects CaseNET to Enhance Care Services Infrastructure
8. Centre De Sante et de Services Sociaux Haut-Richelieu-Rouville in Quebec Selects Alcatel-Lucent and SSP Telecom to Upgrade its Communications Infrastructure
9. Novel semiconductor structure bends light wrong way -- the right direction for many applications
10. Palmer College of Chiropractic Selects Colubris Networks to Provide Wireless Infrastructure at Three U.S. Campuses
11. Pharmos Restructures Operations in Israel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic Research will demonstrate its ... Merchants (NAMM) winter trade show, Booth #2876, at the Anaheim Convention Center in ... the gold standard for high-definition, in-ear earphones. This classic earphone has been updated ...
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting ... Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted ... providers. , Produced by Zeltiq, CoolSculpting is approved by the Food and Drug ...
(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons from New York’s ... care practitioners on the latest breakthroughs in the prevention, diagnosis and treatment of ... according to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive Officer of SightMD ...
(Date:1/17/2017)... ... ... Neil H. Greco Insurance Agency, a northern New Jersey firm that provides ... a charity drive to raise awareness of heart disease and promote habits that improve ... is responsible for 1 in every 4 deaths at the national level each year. ...
(Date:1/17/2017)... ... January 17, 2017 , ... Livionex, Inc., a Silicon Valley healthcare ... blind clinical study for its dental gel that shows significant reduction in plaque levels ... containing triclosan. The study was conducted at the Beckman Laser Institute at UC Irvine ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... -- OrthoAccel ® Technologies, Inc. announces that the ... Effect of Vibration on Molar Distalization," a study that ... Jay Bowman , this prospective, peer-reviewed clinical study concluded ... ® speeds up molar distalization rates in the ... days to move the upper molars into a normal, ...
(Date:1/17/2017)... 2017   Tocagen Inc ., a clinical-stage, cancer-selective gene therapy ... president, research and pharmaceutical development at Tocagen, will present at ... Jan. 17-20 in Miami . ... ... for replicating viruses - what to do when and why Date ...
(Date:1/17/2017)... Jan. 17, 2017  EMD Serono, the biopharmaceutical business ... in the U.S. and Canada , ... joined the company as Senior Vice President and Head ... Smith will oversee the Fertility and Endocrinology businesses in ... launched its first product last year with Gidget™, a ...
Breaking Medicine Technology: